Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
Summary
This trial includes dose-escalating part (phase 1) and dose confirming part, to prove the safety and efficacy of VGN-R09b to treat patients with severe AADC deficiency
Official title: An Open, Dose-escalating and Dose Confirmation Trial to Evaluate the Safety and Efficacy of VGN-R09b by Intra Putamen Injection in Patients With Severe Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Key Details
Gender
All
Age Range
18 Months - 8 Years
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2024-07-02
Completion Date
2030-09-20
Last Updated
2026-04-03
Healthy Volunteers
No
Interventions
VGN-R09b injection
Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
Locations (1)
Shanghai
Shanghai, Shanghai Municipality, China